Garyphallia Poulakou
A5001044836- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Antibiotic Use and Resistance
- Antibiotic Resistance in Bacteria
- Nosocomial Infections in ICU
- Long-Term Effects of COVID-19
- Antibiotics Pharmacokinetics and Efficacy
- Pneumonia and Respiratory Infections
- Sepsis Diagnosis and Treatment
- Bacterial Identification and Susceptibility Testing
- Streptococcal Infections and Treatments
- Antimicrobial Resistance in Staphylococcus
- COVID-19 and healthcare impacts
- Respiratory viral infections research
- Urinary Tract Infections Management
- Antifungal resistance and susceptibility
- COVID-19 Impact on Reproduction
- Respiratory Support and Mechanisms
- Cancer Immunotherapy and Biomarkers
- Patient Satisfaction in Healthcare
- Inhalation and Respiratory Drug Delivery
- Intensive Care Unit Cognitive Disorders
- Infective Endocarditis Diagnosis and Management
- Viral Infections and Outbreaks Research
- COVID-19 epidemiological studies
Sotiria General Hospital
2018-2025
National and Kapodistrian University of Athens
2016-2025
University General Hospital Attikon
2007-2024
Duke University Health System
2023
University of Copenhagen
2023
Rigshospitalet
2023
Centre of Excellence for Health, Immunity and Infections
2023
Australian National University
2022
Laiko General Hospital of Athens
2017-2022
European Society of Clinical Microbiology and Infectious Diseases
2022
Summary Emerging evidence shows that severe coronavirus disease 2019 (COVID‐19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character high risk of venous thromboembolism. The incidence thromboembolism among COVID‐19 patients in intensive care units appears to somewhat higher compared reported other studies including such conditions. D‐dimer might help early recognition these high‐risk and also predict outcome....
Abstract Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative increased risk progression coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at progressing failure as identified by plasma suPAR ≥6 ng ml −1 , 85.9% ( n = 510) whom were receiving dexamethasone. At day 28, adjusted...
We describe the emergence and spread of Klebsiella pneumoniae carbapenemase 2 (KPC-2)-producing K. at a Greek University hospital.Isolates with carbapenem minimum inhibitory concentration >1 microg/mL negative EDTA-imipenem disk synergy test result were submitted to boronic acid polymerase chain reaction (PCR) for KPC gene sequencing. Records from patients who had KPC-2-producing isolated retrospectively reviewed. Clinical isolates molecular typing using pulsed-field gel electrophoresis,...
It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19.A total 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous 100 mg once daily for 10 days. Primary outcome SRF incidence by day 14 defined as any ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes 30-day mortality and inflammatory mediators; 28-day WHO-CPS explored. Propensity-matched standard-of care comparators...
In a recent study of our group with the acronym ACTIVATE, Bacillus Calmete-Guérin (BCG) vaccination reduced occurrence new infections compared to placebo in elderly. Most benefit was found for respiratory infections. The ACTIVATE-2 launched assess efficacy BCG against coronavirus disease 2019 (COVID-19). this multicenter, double-blind trial, 301 volunteers aged 50 years or older were randomized (1:1) be vaccinated placebo. trial end points incidence COVID-19 and presence anti–severe acute...
The aim of this document was to develop standardized research definitions invasive fungal diseases (IFD) in non-neutropenic, adult patients without classical host factors for IFD, admitted intensive care units (ICUs). After a systematic assessment the diagnostic performance IFD target population already existing and laboratory tests, consensus were developed by panel experts using RAND/UCLA appropriateness method. Standardized proven candidiasis, probable deep-seated aspergillosis, pulmonary...
Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes long-term sepsis sequelae remain unclear.Objectives: To investigate if PCT guidance may reduce incidence of infection-associated adverse events sepsis.Methods: In this multicenter trial, 266 patients with (by Sepsis-3 definitions) acute pyelonephritis, or primary bloodstream infection were randomized (1:1) to...